Microbes and the Developing Gastrointestinal Tract

Abstract

During the course of mammalian evolution, there has been a close relationship between microbes residing in the gastrointestinal (GI) tract and the mammalian host. Although the host provides the microbes with a warm environment and nutrients, they, in turn, undergo various metabolic processes that aid the host. The host has developed weapons against microbes that are considered foreign, as well as mechanisms to tolerate and live synergistically with most of the microbes in the GI tract. This relationship is proving to be important not only in the neonatal period and during infancy, but it is becoming increasingly evident that microbial colonization in early life may affect the individual's health throughout life. Here we will review this relationship in terms of health and disease, with a focus on the aspects of this relationship during maturation of the host.

Get full access to this article

View all access options for this article.

References

Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad SciUSA. 2003;100:10452– 10459.

Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283– 307.

Hooper LV, Stappenbeck TS, Hong CV, Gordon J. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003;4:269– 273.

Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004 ;12:129– 134.

Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad SciUSA. 2002 ;99:15451– 15455.

Kien CL. Digestion, absorption, and fermentation of carbohydrates in the newborn. Clin Perinatol. 1996 ;23:211– 228.

Sanderson IR. Short chain fatty acid regulation of signaling genes expressed by the intestinal epithelium. J Nutr. 2004 ;134:2450S– 2454S.

Bourlioux P, Koletzko B, Guarner F, Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium “The Intelligent Intestine,” held in Paris, June 14, 2002. Am J Clin Nutr. 2003 ;78:675– 683.

Snyder JD, Walker WA. Structure and function of intestinal mucin: developmental aspects. Int Arch Allergy Appl Immunol. 1987 ;82:351– 356.

10.

Swift S, Vaughan EE, de Vos WM. Quorum sensing within the gut ecosystem. Microbial Ecol Health Dis. 2000 ;12:81– 92.

11.

Schumann A, Nutten S, Donnicola D, et al. Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics. 2005 ;23:235– 245.

12.

Caicedo RA, Schanler RJ, Li N, Neu J. The developing intestinal ecosystem: implications for the neonate. Pediatr Res. 2005 ;58:625– 628.

13.

Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res. 2001 ;50:553– 562.

14.

Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. Eur J Pediatr. 1999 ;158(suppl 1):S18– S22.

15.

Speer CP. Pre- and postnatal inflammatory mechanisms in chronic lung disease of preterm infants. Paediatr Respir Rev. 2004 ;5(suppl A):S241– S244.

16.

Deitch EA, Xu D, Kaise VL. Role of the gut in the development of injury- and shock-induced SIRS and MODS: the gut-lymph hypothesis, a review. Front Biosci. 2006 ;11:520– 528.

17.

Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 2005 ;94:386– 393.

18.

Vanderhoof JA, Young RJ. The role of probiotics in the treatment of intestinal infections and inflammation. Curr Opin Gastroenterol. 2001;17:58– 62.

19.

Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005 ;147:192– 196.

20.

Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005 ;115:1– 4.

21.

Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants: a prospective double-blind study. Biol Neonate. 2002 ;82:103– 108.

22.

Martin R, Langa S, Reviriego C, et al. Human milk is a source of lactic acid bacteria for the infant gut. J Pediatr. 2003 ;143:754– 758.

23.

Martin R, Olivares M, Marin ML, Fernandez L, Xaus J, Rodriguez JM. Probiotic potential of 3 Lactobacilli strains isolated from breast milk. J Hum Lact. 2005 ;21:8– 17.

24.

Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999 ;3:197– 202.

25.

Bell EF. Preventing necrotizing enterocolitis: what works and how safe? Pediatrics. 2005 ;115:173– 174.

26.

Kliegman RM, Willoughby RE. Prevention of necrotizing enterocolitis with probiotics. Pediatrics. 2005 ;115:171– 172.

27.

Zhang L, Li N, Caicedo R, Neu J. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr. 2005 ;135:1752– 1756.

28.

Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005 ;115:178– 181.

29.

Kunz AN, Fairchok MP, Noel JM. Lactobacillus sepsis associated with probiotic therapy [letter]. Pediatrics. 2005 ;116:517 .

30.

De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005;24:278– 280.

31.

Riquelme AJ, Calvo MA, Guzman AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003 ;36:41– 43.

32.

Rijnders BJ, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host [letter]. Intensive Care Med. 2000;26:825 .

33.

Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002 ;347:911– 920.

34.

Rook GA, Brunet LR. Microbes, immunoregulation, and the gut. Gut. 2005;54:317– 320.

35.

Rachmilewicz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004 ;126:520– 528.

36.

Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005 ;115:695– 702.

37.

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004 ;118:229– 241.

38.

Pessi T, Sutas Y, Saxelin M, Kallioinen H, Isolauri E. Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria. Appl Environ Microbiol. 1999 ;65:4725– 4728.

39.

Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000;289:1560– 1563.

40.

Savidge TC, Newman PG, Pan WH, et al. Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signaling. Pediatr Res. 2006;59:89– 95.

41.

Madara J. Building an intestine—architectural contributions of commensal bacteria. N Engl J Med. 2004 ;351:1685– 1686.

42.

Collier-Hyams LS, Sloane V, Batten BC, Neish AS. Cutting edge: bacterial modulation of epithelial signaling via changes in neddylation of cullin-1. J Immunol. 2005 ;175:4194– 4198.

43.

Laron Z. Interplay between heredity and environment in the recent explosion of type 1 childhood diabetes mellitus. J Med Genet. 2002;115:4– 7.

44.

Bach JF. A toll-like trigger for autoimmune disease. Nat Med. 2005;11:120– 121.

45.

Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. Clin Exp Allergy. 1999;29:766– 771.

46.

Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol. 2004 ;20:565– 571.

47.

Johnson CC, Ownby DR, Alford SH, et al. Antibiotic exposure in early infancy and risk for childhood atopy. J Allergy Clin Immunol. 2005;115:1218– 1224.

48.

Chappel CI, Chappel WR. The discovery and development of the BB rat colony: an animal model of spontaneous diabetes mellitus. Metabolism. 1983 ;32(7 Suppl 1):8– 10.

49.

Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107– 118.

50.

Meddings JB, Jarand J, Urbanski SJ, Hardin J, Gall DG. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol. 1999 ;276(4 pt 1):G951– G957.

51.

Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001 ;292:1115– 1118.

52.

Calcinaro FDS, Marinaro M, Candeloro P, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005 ;48:1565– 1575.

53.

Samuelsson U, Ludvigsson J. The concentrations of short-chain fatty acids and other microflora-associated characteristics in faeces from children with newly diagnosed type 1 diabetes and control children and their family members. Diabet Med. 2004 ;21:64– 67.

54.

Mordes JP, Bortell R, Blankenhorn EP, Rossini AA, Greiner DL. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J. 2004;45:278– 291.

55.

Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere. Clin Immunol. 2001 ;100:134– 143.

56.

Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 ;357:1076– 1079.

57.

Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol. 2005;174:3237– 3246.

58.

Kohse KP, Carl A, Steinbach G. Whole blood interleukin-8 concentrations in capillary and cord blood of neonates for the diagnosis of systemic inflammatory states. Clin Lab. 2002 ;48:497– 503.

59.

Christen U, von Herrath MG. Infections and autoimmunity: good or bad? J Immunol. 2005 ;174:7481– 7486.

60.

Rossini AA. Autoimmune diabetes and the circle of tolerance. Diabetes. 2004;53:267– 275.

61.

Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655– 664.

62.

Powrie F. Immune regulation in the intestine: a balancing act between effector and regulatory T cell responses. Ann N Y Acad Sci. 2004;1029:132– 141.

63.

Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003 ;3:331– 341.

64.

Sakaguchi SN, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995 ;155:1151– 1164.

65.

Wing K, Suri-Payer E, Rudin A. CD4+CD25+-regulatory T cells from mouse to man. Scand J Immunol. 2005 ;62:1– 15.

66.

Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 ;6:345– 352.

67.

Wickelgren I. Immunology: policing the immune system. Science. 2004;306:596– 599.

68.

Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol. 2003 ;15:430– 435.

69.

Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004 ;199:1479– 1489.

70.

Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004 ;22:531– 562.

71.

Watanabe T, Yamori M, Kita T, Chiba T, Wakatsuki Y. CD4+CD25+ T cells regulate colonic localization of CD4 T cells reactive to a microbial antigen. Inflamm Bowel Dis. 2005 ;11:541– 550.

72.

Elliott DE, Summers RW, Weinstock JV. Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol. 2005 ;21:51– 58.

73.

Makita S, Kanai T, Oshima S, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004;173:3119– 3130.

74.

Strober W. Epithelial cells pay a Toll for protection. Nat Med. 2004;10:898– 900.

75.

Zipris D, Hillebrands JL, Welsh RM, et al. Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J Immunol. 2003 ;170:3592– 3602.

76.

Kukreja ACG, Marker J, Zhang C, et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest. 2002 ;109:131– 140.

77.

Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005 ;6:331– 337.

78.

Wildhaber BE, Yang H, Spencer AU, Drongowski RA, Teitelbaum DH. Lack of enteral nutrition-effects on the intestinal immune system. J Surg Res. 2005 ;123:8– 16.

79.

Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005 ;128:1868– 1878.

80.

Gad M. Regulatory T cells in experimental colitis. Curr Top Microbiol Immunol. 2005 ;293:179– 208.

81.

Maloy KJ, Antonell LR, Lefevre M, Powrie F. Cure of innate intestinal immune pathology by CD4+CD25+ regulatory T cells. Immunol Lett. 2005 ;97:189– 192.